

# Patricia Kaaijk

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1995480/publications.pdf>

Version: 2024-02-01

32  
papers

707  
citations

567144

15  
h-index

580701

25  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1029  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave. <i>Journal of Epidemiology and Community Health</i> , 2021, 75, 489-495.	2.0	88
2	Expression of a Natural Tumor Antigen by Thymic Epithelial Cells Impairs the Tumor-Protective CD4+ T-Cell Repertoire. <i>Cancer Research</i> , 2005, 65, 6443-6449.	0.4	55
3	Improved Production Process for Native Outer Membrane Vesicle Vaccine against <i>Neisseria meningitidis</i> . <i>PLoS ONE</i> , 2013, 8, e65157.	1.1	50
4	Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. <i>Vaccine</i> , 2013, 31, 1065-1071.	1.7	45
5	Expression of CD44 splice variants in human primary brain tumors. <i>Journal of Neuro-Oncology</i> , 1995, 26, 185-190.	1.4	43
6	Differential expression of CD44 splice variants in the normal human central nervous system. <i>Journal of Neuroimmunology</i> , 1997, 73, 70-76.	1.1	40
7	Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands. <i>BMC Infectious Diseases</i> , 2012, 12, 35.	1.3	39
8	Mumps-specific cross-neutralization by MMR vaccine-induced antibodies predicts protection against mumps virus infection. <i>Vaccine</i> , 2016, 34, 4166-4171.	1.7	35
9	Vaccination against RSV. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1263-1267.	1.4	28
10	Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 337-344.	1.4	28
11	A Third Dose of Measles-Mumps-Rubella Vaccine to Improve Immunity Against Mumps in Young Adults. <i>Journal of Infectious Diseases</i> , 2020, 221, 902-909.	1.9	25
12	High concentration of Daunorubicin and Daunorubicinol in human malignant astrocytomas after systemic administration of liposomal Daunorubicin. <i>Journal of Neuro-Oncology</i> , 2001, 53, 267-271.	1.4	23
13	Mumps infection but not childhood vaccination induces persistent polyfunctional CD8 + T-cell memory. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1908-1911.e12.	1.5	21
14	In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia. <i>Haematologica</i> , 2006, 91, 17-23.	1.7	21
15	Oxygenation and response to irradiation of organotypic multicellular spheroids of human glioma. <i>Anticancer Research</i> , 2003, 23, 1461-6.	0.5	17
16	Routine vaccination against MenB. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 310-316.	1.4	14
17	Dynamics of the serologic response in vaccinated and unvaccinated mumps cases during an epidemic. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1754-1761.	1.4	14
18	Dynamics of the Antibody Response After a Third Dose of Measles-Mumps-Rubella Vaccine Indicate a Slower Decline Compared With a Second Dose. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa505.	0.4	14

#	ARTICLE	IF	CITATIONS
19	The Human CD4 <sup>+</sup> T Cell Response against Mumps Virus Targets a Broadly Recognized Nucleoprotein Epitope. <i>Journal of Virology</i> , 2019, 93, .	1.5	11
20	Contribution of Influenza Viruses, Other Respiratory Viruses and Viral Co-Infections to Influenza-like Illness in Older Adults. <i>Viruses</i> , 2022, 14, 797.	1.5	11
21	Nonclinical vaccine safety evaluation: advantages of continuous temperature monitoring using abdominally implanted data loggers. <i>Journal of Applied Toxicology</i> , 2013, 33, 521-526.	1.4	10
22	Parentsâ€™ attitude toward multiple vaccinations at a single visit with alternative delivery methods. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2483-2489.	1.4	10
23	Vaccination against Lyme disease: Are we ready for it?. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 757-762.	1.4	9
24	Development of an IFN $\gamma$ ELISPOT for the analysis of the human T cell response against mumps virus. <i>Journal of Immunological Methods</i> , 2016, 431, 52-59.	0.6	8
25	Identification of Naturally Processed Mumps Virus Epitopes by Mass Spectrometry: Confirmation of Multiple CD8 <sup>+</sup> T-Cell Responses in Mumps Patients. <i>Journal of Infectious Diseases</i> , 2019, 221, 474-482.	1.9	8
26	Effect of single dose irradiation on human glioblastoma spheroids in vitro. <i>Oncology Reports</i> , 2004, 11, 477-85.	1.2	8
27	Preclinical evaluation of MenB vaccines: prerequisites for clinical development. <i>Expert Review of Vaccines</i> , 2013, 12, 31-42.	2.0	7
28	Antibody Levels at 3-Years Follow-Up of a Third Dose of Measles-Mumps-Rubella Vaccine in Young Adults. <i>Vaccines</i> , 2022, 10, 132.	2.1	7
29	Past, current and future protocols for combined modality therapy in childhood medulloblastoma. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 79-90.	1.1	5
30	Novel mumps virus epitopes reveal robust cytotoxic T cell responses after natural infection but not after vaccination. <i>Scientific Reports</i> , 2021, 11, 13664.	1.6	5
31	Genetic Analysis Reveals Differences in CD8 <sup>+</sup> T Cell Epitope Regions That May Impact Cross-Reactivity of Vaccine-Induced T Cells against Wild-Type Mumps Viruses. <i>Vaccines</i> , 2021, 9, 699.	2.1	4
32	Longitudinal Characterization of the Mumps-Specific HLA-A2 Restricted T-Cell Response after Mumps Virus Infection. <i>Vaccines</i> , 2021, 9, 1431.	2.1	1